Cargando…
South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
BACKGROUND: Chronic myeloid leukaemia (CML) is a haematological malignancy characterised by the translocation t(9;22)(q34;q11.2), resulting in a constitutively active tyrosine kinase. Globally, overall survival of blast crisis phase (BC) CML is one year. Newer tyrosine kinase inhibitors and allogene...
Autores principales: | Hodkinson, Katherine E., Bouwer, Nikki, Vaughan, Jenifer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AOSIS
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210180/ https://www.ncbi.nlm.nih.gov/pubmed/35747555 http://dx.doi.org/10.4102/ajlm.v11i1.1578 |
Ejemplares similares
-
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022) -
Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia.
por: Zalcberg, J. R., et al.
Publicado: (1986) -
Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
por: Gangal, S. G., et al.
Publicado: (1979) -
Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases
por: Gu, Ruixin, et al.
Publicado: (2022) -
Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)